Mitochondrial Derived Peptides as a Source for Novel Therapeutics

Time: 2:00 pm
day: Day One


  • Analyzing how the effects of some mitochondrially encoded peptides are not limited to local regulation, but have important roles to play in critical biological pathways
  • Exploring CB4211, a novel analog of MOTS-c being developed for the treatment of NASH and obesity, including positive clinical data from a multi-center, randomized, double blind placebo-controlled trial
  • Examining how CB5138-3 has the potential to be a differentiated therapy for the treatment of IPF and other fibrotic diseases